GlaxoSmithKline (Italy)

Cost-effectiveness of a single dose of the adjuvanted respiratory syncytial virus preFusion protein 3 vaccine over 5 years and its potential public health impact among older adults in Italy

BACKGROUND: Respiratory syncytial virus-associated acute respiratory illness (RSV-ARI) is an underrecognized cause of illness in older adults aged ≥ 75 years (OAs) and individuals at increased risk (AIR), contributing to a substantial disease burden. AS01E-adjuvanted RSV PreFusio...